# Quantum Labs - Financial Details

## Revenue & Growth
- **ARR**: $800K ($66.7K MRR)
- **Growth Rate**: 12% MoM (290% annualized)
- **NRR**: 115% (moderate expansion)
- **Customer Count**: 8 pharma companies

## Unit Economics
- **Average ACV**: $100K
- **Gross Margin**: 65% (compute + data costs higher than SaaS)
- **CAC**: $180K (long enterprise sales cycles)
- **LTV**: $460K (based on 4-year retention assumed)
- **LTV/CAC Ratio**: 2.5x (⚠️ borderline, needs improvement)
- **Payback Period**: 22 months

## Burn & Runway
- **Monthly Burn**: $350K
- **Cash Balance**: $4.9M
- **Runway**: 14 months ⚠️ **Tight for seed stage**

## Customer Breakdown
- **Big Pharma (>$200K ACV)**: 3 customers, 72% of ARR
- **Biotech ($50K-$200K)**: 5 customers, 28% of ARR

## Revenue Concentration
- **Top Customer (Merck)**: $224K ACV (28% of ARR) ⚠️ **High concentration risk**
- **Top 3 Customers**: 72% of ARR ⚠️ **Risky**

## Key Concerns
⚠️ **Customer Concentration**: If Merck churns, lose 28% of revenue
⚠️ **Tight Runway**: 14 months without new funding is risky
⚠️ **High CAC**: $180K CAC with 22-month payback is concerning
⚠️ **Proof Point Gap**: Need a drug in trials to validate platform
⚠️ **Churn Risk**: Only 8 customers, each churn is ~12.5% revenue impact

## Positive Signals
✓ **Retention**: 115% NRR shows customers are expanding
✓ **Pipeline**: $2.4M in signed contracts not yet recognized
✓ **Team Quality**: World-class scientists with relevant publications
✓ **Market Timing**: AI for drug discovery is a hot category

## Decision Factors
**PASS if:**
- Runway concerns + customer concentration too risky
- Need to see clinical proof point first
- CAC payback period too long

**INVEST if:**
- Believe in team's ability to land 2-3 more Big Pharma deals in next 6 months
- See clear path to drug in trials within 18 months
- Value strategic positioning in AI×biotech intersection
